← Leaderboards
Andrea Schietinger
Sloan-Kettering Inst Can Research
$11,046,356
Attributed
$11,046,356
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3.4M · FY2013–25$5M$3.8M$2.5M$1.3M$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,046,356 · 6
By mechanism
R01$4,454,823 · 2
U54$2,926,494 · 1
DP2$2,578,500 · 1
R00$746,997 · 1
K99$339,542 · 1
Top collaborators
No co-investigators on record.
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- Willie H Mark$8,877,496
- Kayvan R Keshari$12,246,491
- Taha Merghoub$4,342,237
- Tuomas Tammela$7,490,282
- Morgan A Huse$10,543,572
Others in their field
Top investigators on “T Cell Differentiation”
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- John M Lachin · George Washington University$118,672,444
- David M Nathan · Massachusetts Institute Of Technology$118,672,444
- David Heimbrook · Leidos Biomedical Research, Inc.$116,528,280
- Israel David Goldman · Yeshiva University$52,846,708
Research focus
T Cell DifferentiationCellsMalignant NeoplasmsMouse ModelT-LymphocyteClinically RelevantMediatingAntigensTumorTumor AntigensInsightChromatinCancer CellCancer ImmunotherapyCd8-Positive T-LymphocytesMolecularFunctional DisorderComplexEpigenetic ProcessImprintImmuneTranscription FactorInnovationPrograms
Grant awards (17)
Autoimmune Stem-like CD8 T cells in Type 1 Diabetes$867,074
R01 · FY2025 · AI · contact PI
TOX-driven CD8 T cell differentiation and dysfunction in tumors$602,850
R01 · FY2025 · CA · contact PI
Autoimmune Stem-like CD8 T cells in Type 1 Diabetes$879,657
R01 · FY2024 · AI · contact PI
TOX-driven CD8 T cell differentiation and dysfunction in tumors$577,535
R01 · FY2024 · CA · contact PI
Autoimmune Stem-like CD8 T cells in Type 1 Diabetes$910,690
R01 · FY2023 · AI · contact PI
TOX-driven CD8 T cell differentiation and dysfunction in tumors$617,017
R01 · FY2023 · CA · contact PI
Tumor-specific T cell state dynamics and heterogeneity in early tumorigenesis$633,251
U54 · FY2020 · CA · contact PI
Tumor-specific T cell state dynamics and heterogeneity in early tumorigenesis$591,768
U54 · FY2019 · CA · contact PI
Tumor-specific T cell state dynamics and heterogeneity in early tumorigenesis$620,640
U54 · FY2018 · CA · contact PI
Spatiotemporal regulation of T cell fate decisions in cancer$2,578,500
DP2 · FY2017 · CA · contact PI
Tumor-specific T cell state dynamics and heterogeneity in early tumorigenesis$540,239
U54 · FY2017 · CA · contact PI
Molecular and Epigenetic Programs Underlying T cell Tolerance to Tumor Antigens$248,999
R00 · FY2017 · CA · contact PI
Tumor-specific T cell state dynamics and heterogeneity in early tumorigenesis$540,596
U54 · FY2016 · CA · contact PI
Molecular and Epigenetic Programs Underlying T cell Tolerance to Tumor Antigens$248,999
R00 · FY2016 · CA · contact PI
Molecular and Epigenetic Programs Underlying T cell Tolerance to Tumor Antigens$248,999
R00 · FY2015 · CA · contact PI
Molecular and Epigenetic Programs Underlying T cell Tolerance to Tumor Antigens$169,771
K99 · FY2014 · CA · contact PI
Molecular and Epigenetic Programs Underlying T cell Tolerance to Tumor Antigens$169,771
K99 · FY2013 · CA · contact PI